Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non–Small-cell Lung Cancer

Clinical Lung Cancer

Volumn 17, Issue 6, 2016, Pages 474-482

  Matikas, Alexios ^a   Kentepozidis, Nikolaos ^a   Georgoulias, Vassilis ^a   Kotsakis, Athanasios ^a  

^a Hellenic Oncology Research Group   (Greece)

Author keywords

Alectinib; ALK inhibitor; Ceritinib; EML4 ALK; NSCLC

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BRIGATINIB; CERITINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; K RAS PROTEIN; LORLATINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG TREATMENT FAILURE; EXON; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; NON SMALL CELL LUNG CANCER; REVIEW; SIGNAL TRANSDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MANAGEMENT; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84994508141     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.05.006     Document Type: Review

References (87)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. 2 Scagliotti, G.V., Parikh, P., von Pawel, J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008), 3543–3551.
3. 3 The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
4. 4 The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
5. 5 Rosell, R., Carcereny, E., Gervais, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.
6. 6 Yang, J.C., Wu, Y.L., Schuler, M., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16 (2015), 141–151.
7. 7 Mok, T.S., Wu, Y.L., Thongprasert, S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
8. 8 Solomon, B.J., Mok, T., Kim, D.W., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
9. 9 Soda, M., Choi, Y.L., Enomoto, M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
10. 10 Choi, Y.L., Takeuchi, K., Soda, M., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68 (2008), 4971–4976.
11. 11 Koivunen, J.P., Mermel, C., Zejnullahu, K., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14 (2008), 4275–4283.
12. 12 Ou, S.H., Bartlett, C.H., Mino-Kenudson, M., Cui, J., Iafrate, A.J., Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17 (2012), 1351–1375.
13. 13 Takeuchi, K., Choi, Y.L., Togashi, Y., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15 (2009), 3143–3149.
14. 14 Hrustanovic, G., Olivas, V., Pazarentzos, E., et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med 21 (2015), 1038–1047.
15. 15 Mengoli, M.C., Barbieri, F., Bertolini, F., Tiseo, M., Rossi, G., K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature. Lung Cancer 93 (2016), 55–58.
16. 16 Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247–4253.
17. 17 Rodig, S.J., Mino-Kenudson, M., Dacic, S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15 (2009), 5216–5223.
18. 18 Camidge, D.R., Kono, S.A., Flacco, A., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16 (2010), 5581–5590.
19. 19 Conklin, C.M., Craddock, K.J., Have, C., Laskin, J., Couture, C., Ionescu, D.N., Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8 (2013), 45–51.
20. 20 Cruz-Rico, G., Morales-Oyarvide, V., Aviles-Salas, A., et al. Diagnosis of EML4-ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with non-small cell lung cancer: the Latin American experience. Ann Oncol 25:suppl (2014), iv426–iv470.
21. 21 Takeuchi, K., Togashi, Y., Kamihara, Y., et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 27 (2016), 185–192.
22. 22 Takeuchi, K., Choi, Y.L., Soda, M., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14 (2008), 6618–6624.
23. 23 Pekar-Zlotin, M., Hirsch, F.R., Soussan-Gutman, L., et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20 (2015), 316–322.
24. 24 Christensen, J.G., Zou, H.Y., Arango, M.E., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6 (2007), 3314–3322.
25. 25 Camidge, D.R., Bang, Y.J., Kwak, E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13 (2012), 1011–1019.
26. 26 Kim, D., Ahn, M., Shi, Y., et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol, 30(suppl), 2012 abstract 7533.
27. 27 Shaw, A.T., Kim, D.W., Nakagawa, K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
28. 28 Kim, D., Mehra, R., Tan, D., et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. J Clin Oncol, 32(suppl), 2014, 5s abstract 8003.
29. 29 Mok, T., Dpigel, D., Felip, E., et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol, 33(suppl), 2015 abstract 8059.
30. 30 Felip, E., Orlov, S., Park, K., et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol, 33(suppl), 2015 abstract 8060.
31. 31 Ohe, Y., Nishio, M., Kiura, K., et al. A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): updates on progression free survival (PFS) and safety results from AF-001JP. J Clin Oncol, 33(suppl), 2015 abstract 8061.
32. 32 Ou, S.I., Ahn, J.S., De Petris, L., et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34 (2016), 661–668.
33. 33 Shaw, A.T., Gandhi, L., Gadgeel, S., et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17 (2016), 234–242.
34. 34 Camidge, R., Bazhenova, L., Salgia, R., et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). J Clin Oncol, 33(suppl), 2015 abstract 8062.
35. 35 Shaw, A., Bauer, T., Felip, E., et al. Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol, 33(suppl), 2015 abstract 8018.
36. 36 Patnaik, A., LoRussa, P., Ball, H., et al. Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. J Clin Oncol, 31(suppl), 2013 abstract 2602.
37. 37 Horn, L., Infante, J., Blumenschein, G., et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol, 32(suppl), 2014, 5s abstract 8030.
38. 38 Weiss, G., Sachdev, J., Infante, J., et al. Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations. J Clin Oncol, 32(suppl), 2014 abstract e19005.
39. 39 Choi, Y.L., Soda, M., Yamashita, Y., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363 (2010), 1734–1739.
40. 40 Katayama, R., Shaw, A.T., Khan, T.M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med, 4, 2012, 120ra117.
41. 41 Katayama, R., Friboulet, L., Koike, S., et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20 (2014), 5686–5696.
42. 42 Sasaki, T., Koivunen, J., Ogino, A., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71 (2011), 6051–6060.
43. 43 Doebele, R.C., Pilling, A.B., Aisner, D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18 (2012), 1472–1482.
44. 44 Katayama, R., Khan, T.M., Benes, C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 108 (2011), 7535–7540.
45. 45 Boland, J.M., Jang, J.S., Li, J., et al. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol 8 (2013), 574–581.
46. 46 Rossing, H.H., Grauslund, M., Urbanska, E.M., et al. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Res Notes, 6, 2013, 489.
47. 47 Ji, C., Zhang, L., Cheng, Y., et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 15 (2014), 570–577.
48. 48 Miyamoto, S., Ikushima, S., Ono, R., et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol 46 (2016), 170–173.
49. 49 Friboulet, L., Li, N., Katayama, R., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 (2014), 662–673.
50. 50 Zou, H.Y., Friboulet, L., Kodack, D.P., et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28 (2015), 70–81.
51. 51 Zou, H.Y., Li, Q., Engstrom, L.D., et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A 112 (2015), 3493–3498.
52. 52 Shaw, A.T., Friboulet, L., Leshchiner, I., et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 374 (2016), 54–61.
53. 53 De Braud, F., Niger, M., Damian, S., et al. Alka-372-001: first-in-human, phase I study of entrectinib—an oral pan-TRK, ROS1, and ALK inhibitor—in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol, 33(suppl), 2015 abstract 2517.
54. 54 Cheng, M., Quail, M.R., Gingrich, D.E., et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 11 (2012), 670–679.
55. 55 Sorensen, J.B., Hansen, H.H., Hansen, M., Dombernowsky, P., Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6 (1988), 1474–1480.
56. 56 Sperduto, P.W., Kased, N., Roberge, D., et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30 (2012), 419–425.
57. 57 Rangachari, D., Yamaguchi, N., VanderLaan, P.A., et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88 (2015), 108–111.
58. 58 Costa, D.B., Kobayashi, S., Pandya, S.S., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29 (2011), e443–e445.
59. 59 Johung, K.L., Yeh, N., Desai, N.B., et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34 (2016), 123–129.
60. 60 Costa, D.B., Shaw, A.T., Ou, S.H., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33 (2015), 1881–1888.
61. 61 Solomon, B., Felip, E., Blackhall, F., et al. Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st-line crizotinib vs pemetrexed-platinum chemotherapy (PPC) in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC). Ann Oncol 25 (2014), iv426–iv470.
62. 62 Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., Sakamoto, H., Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74 (2014), 1023–1028.
63. 63 Gainor, J.F., Chi, A.S., Logan, J., et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol 11 (2016), 256–260.
64. 64 Takeda, M., Okamoto, I., Nakagawa, K., Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8 (2013), 654–657.
65. 65 Weickhardt, A.J., Scheier, B., Burke, J.M., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7 (2012), 1807–1814.
66. 66 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer version 4. 2016 Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Accessed: January 18, 2016.
67. 67 Ou, S.H., Janne, P.A., Bartlett, C.H., et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25 (2014), 415–422.
68. 68 Chiari, R., Metro, G., Iacono, D., et al. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: results of a multicenter analysis. Lung Cancer 90 (2015), 255–260.
69. 69 Paz-Ares, L., de Marinis, F., Dediu, M., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13 (2012), 247–255.
70. 70 Shaw, A.T., Varghese, A.M., Solomon, B.J., et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 24 (2013), 59–66.
71. 71 Park, S., Park, T.S., Choi, C.M., et al. Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. Clin Lung Cancer 16 (2015), e83–e89.
72. 72 Whitesell, L., Lindquist, S.L., HSP90 and the chaperoning of cancer. Nat Rev Cancer 5 (2005), 761–772.
73. 73 Trepel, J., Mollapour, M., Giaccone, G., Neckers, L., Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10 (2010), 537–549.
74. 74 Neckers, L., Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8 (2002), S55–S61.
75. 75 Chen, Z., Sasaki, T., Tan, X., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70 (2010), 9827–9836.
76. 76 Normant, E., Paez, G., West, K.A., et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30 (2011), 2581–2586.
77. 77 Sequist, L.V., Gettinger, S., Senzer, N.N., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28 (2010), 4953–4960.
78. 78 Sang, J., Acquaviva, J., Friedland, J.C., et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 3 (2013), 430–443.
79. 79 Socinski, M.A., Goldman, J., El-Hariry, I., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19 (2013), 3068–3077.
80. 80 Garon, E., Moran, T., Barlesi, F., et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 30(suppl), 2012 abstract 7543.
81. 81 Ilie, M., Long, E., Butori, C., et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 23 (2012), 2907–2913.
82. 82 Pailler, E., Adam, J., Barthelemy, A., et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 31 (2013), 2273–2281.
83. 83 Newman, A.M., Bratman, S.V., To, J., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20 (2014), 548–554.
84. 84 Nilsson, R.J., Karachaliou, N., Berenguer, J., et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget 7 (2016), 1066–1075.
85. 85 Skov, B.G., Hogdall, E., Clementsen, P., et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS 123 (2015), 108–115.
86. 86 Hellmann M, Garon E, Gandhi L, et al. Efficacy of pembrolizumab in key subgroups of patients with advanced NSCLC. Presented at the 16th World Conference on Lung Cancer, 2015; abstract 3057.
87. 87 Djalalov, S., Beca, J., Hoch, J.S., et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 32 (2014), 1012–1019.